LTS Lohmann Therapie-Systeme AG (LTS), a world-class pharmaceutical technology company headquartered in Andernach, Germany, and Livzon Pharmaceutical Group Inc. (Livzon), a leading PRC pharmaceutical company, announced today that the companies have entered an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

Under the terms of the agreement, LTS shall perform certain pre-clinical studies for the product development, clinical trial sample manufacturing and supply, while Livzon shall be responsible for the clinical studies, obtaining registration approval, and commercialization of Asenapine TTS in China.

Livzon CEO Mr Yanggang Tang said: “Livzon has always been committed to a long-term partnership with global companies to develop therapeutic products based on top-notch technologies, which would potentially benefit millions of patients in China. Our collaboration with LTS leverages both companies’ strengths and capabilities, and both teams share the same vision for patient convenience in drug administration and speciality formulation. We are excited and proud to be a partner of LTS in China and to kick off this project in 2020.”

LTS CEO Dr Tim G. Schlange said: “We are delighted to develop the Asenapine transdermal patch as a potentially state-of-the-art innovative therapeutic choice for the benefit of patients in China. Together with our distinguished partner Livzon, a leading pharmaceutical company in China, we leverage our synergistic capabilities in drug and formulation development, regulatory and registration and finally market introduction. We are honoured by the cooperation with Livzon and the agreement marks a strategic milestone for LTS as we target to strengthen our presence in China.”